TD Asset Management Inc Grows Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

TD Asset Management Inc raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 240,358 shares of the company’s stock after buying an additional 4,637 shares during the period. TD Asset Management Inc’s holdings in Teva Pharmaceutical Industries were worth $4,028,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB increased its holdings in Teva Pharmaceutical Industries by 10.3% in the second quarter. Wilmington Savings Fund Society FSB now owns 39,573 shares of the company’s stock valued at $663,000 after buying an additional 3,711 shares in the last quarter. Yousif Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 5.1% in the second quarter. Yousif Capital Management LLC now owns 58,816 shares of the company’s stock valued at $986,000 after purchasing an additional 2,830 shares during the period. MGO One Seven LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $236,000. CWM LLC grew its position in shares of Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock valued at $84,000 after purchasing an additional 767 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its position in shares of Teva Pharmaceutical Industries by 30.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 35,274 shares of the company’s stock valued at $591,000 after purchasing an additional 8,192 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $19.43 on Tuesday. The firm has a market capitalization of $22.28 billion, a PE ratio of -121.41, a PEG ratio of 1.06 and a beta of 0.71. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The firm’s 50-day moving average price is $18.95 and its 200 day moving average price is $17.17. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period in the previous year, the business posted $0.61 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average target price of $25.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.